The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Sponsor
The First People's Hospital of Changzhou
Study ID
NCT02485015
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Stomach Neoplasms

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Cytokine-Induced Killer Cells — BIOLOGICAL
    Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
  • Apatinib — DRUG
    Advanced gastric cancer patients take Apatinib 850mg qd by mouth.

Study Details

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Key Dates

Start date
Jun 30, 2015
Status verified
Feb 2016
Primary completion
Jun 30, 2030
Completion
Jun 30, 2033

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Apatinib alone
    Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
  • Experimental: Apatinib+CIK
    Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.

Primary Outcome Measure

Overall Survival(OS) [ Time Frame: 3 months ]

Related Studies